John Gary Curd ’67

Body

John Curd, a brilliant biotech leader, died peacefully April 20, 2011, in his home in Hillsborough, Calif.

John came to us from Wheat Ridge, Colo. A premed chemistry major, he was a member of Quad and roomed in Murray-Dodge with Peter Colt. After Harvard Medical School (and marriage to Karen Wendel) in 1971 and internship and residency at Mass General, John served at NIH and began a distinguished medical career.

John started in clinical practice and research at Scripps Clinic and Research Foundation, and later became hospital president. In 1991, he transitioned to biotechnology as vice president of clinical development at Genentech, where he discovered new cancer treatments and led the clinical development of Rituxan and the groundbreaking breast-cancer treatment Herceptin. He later served as executive vice president of VaxGen, president and chief medical officer of Novacea, and most recently president and chief medical officer of Threshold Pharmaceuticals. He was known for his brilliance as well as his kindness.

In addition to his passion for advancing science, John enjoyed spending time outdoors with his family, sharing a glass of wine with friends, and working on his cars.

John was a loving husband, inspiring father, and wonderful grandfather. He is survived by Karen, four children, and three grandchildren, to all of whom the class extends its condolences.

No responses yet

Join the conversation

Plain text

Full name and Princeton affiliation (if applicable) are required for all published comments. For more information, view our commenting policy. Responses are limited to 500 words for online and 250 words for print consideration.

Paw in print

Image
The cover of PAW’s November 2025 issue, featuring a photo of a space probe and the headline "Made in Princeton."
The Latest Issue

November 2025

NASA’s new IMAP mission, London’s big data detective, AI challenges in the classroom.